RxSightRXST
About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Employees: 374
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,355% more call options, than puts
Call options by funds: $23.1M | Put options by funds: $1.59M
36% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 64
6.32% less ownership
Funds ownership: 92.3% [Q2] → 85.98% (-6.32%) [Q3]
7% less funds holding
Funds holding: 227 [Q2] → 211 (-16) [Q3]
22% less capital invested
Capital invested by funds: $2.16B [Q2] → $1.69B (-$478M) [Q3]
33% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 49
71% less funds holding in top 10
Funds holding in top 10: 7 [Q2] → 2 (-5) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Stifel Thomas Stephan 31% 1-year accuracy 5 / 16 met price target | 20%upside $40 | Hold Downgraded | 20 Dec 2024 |
Wells Fargo Larry Biegelsen 50% 1-year accuracy 23 / 46 met price target | 26%upside $42 | Equal-Weight Downgraded | 11 Dec 2024 |
UBS Danielle Antalffy 38% 1-year accuracy 5 / 13 met price target | 56%upside $52 | Buy Initiated | 6 Dec 2024 |
Jefferies Young Li 50% 1-year accuracy 1 / 2 met price target | 116%upside $72 | Buy Initiated | 29 Oct 2024 |